Chemical formula: C₁₉H₂₃NO₃ Molecular mass: 313.397 g/mol PubChem compound: 127151
Reboxetine is a highly selective and potent inhibitor of noradrenaline reuptake. Noradrenaline reuptake inhibition and the consequent increase of noradrenaline availability in the synaptic cleft and modification of noradrenergic transmission, reportedly is among the most relevant mechanisms of action of known antidepressant drugs.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N06AX18 | Reboxetine | N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AX Other antidepressants |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| EDRONAX Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Reboxetine is an active ingredient of these brands:
Australia (AU)
Austria (AT)
Croatia (HR)
Estonia (EE)
Ireland (IE)
Israel (IL)
New Zealand (NZ)
Poland (PL)
South Africa (ZA)
Turkey (TR)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
